Thioridazine for treatment of tuberculosis: Promises and pitfalls - 03/12/14
Doi : 10.1016/j.tube.2014.09.001
Noton K. Dutta a, ⁎ 
, Petros C. Karakousis a, b, ⁎
, Petros C. Karakousis a, b, ⁎ a Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
b Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
∗Corresponding authors. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Summary |
The articles by De Knegt et al. and Singh et al. in a recent issue of this Journal address one of the current debates regarding the potential role of thioridazine in the treatment of tuberculosis. This commentary presents a summary of the available evidence, and, emphasizing the need for further research, asks the question: “How far can we go in repurposing thioridazine?”
Le texte complet de cet article est disponible en PDF.Keywords : Mycobacterium tuberculosis, Thioridazine, Efflux pump inhibitor, Adjunctive therapy, Latent TB, Animal model
Plan
© 2014
Elsevier Ltd. Tous droits réservés.
Vol 94 - N° 6
P. 708-711 - décembre 2014 Retour au numéro
Article précédent
- Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy
- Gerjo J. de Knegt, Marian T. ten Kate, Dick van Soolingen, Rob Aarnoutse, Martin J. Boeree, Irma A.J.M. Bakker-Woudenberg, Jurriaan E.M. de Steenwinkel
- MPT64 polymorphisms of Mycobacterium tuberculosis strains suggest ongoing immune evasion
- Yi Jiang, Haican Liu, Kanglin Wan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?